Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia
NCT ID: NCT00134485
Last Updated: 2007-10-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
400 participants
INTERVENTIONAL
2005-03-31
2006-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To evaluate the efficacy and safety of torcetrapib/atorvastatin compared to atorvastatin alone in patients with heterozygous familial hypercholesterolemia
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
torcetrapib/atorvastatin
atorvastatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 18 years of age
Exclusion Criteria
* Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid (high doses)
* Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
* Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
Washington D.C., District of Columbia, United States
Pfizer Investigational Site
Lutz, Florida, United States
Pfizer Investigational Site
Tampa, Florida, United States
Pfizer Investigational Site
Tripler AMC, Hawaii, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Indianapolis, Indiana, United States
Pfizer Investigational Site
Iowa City, Iowa, United States
Pfizer Investigational Site
Auburn, Maine, United States
Pfizer Investigational Site
Scarborough, Maine, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Charlotte, North Carolina, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Madison, Wisconsin, United States
Pfizer Investigational Site
Camperdown, New South Wales, Australia
Pfizer Investigational Site
Woolloongabba, Queensland, Australia
Pfizer Investigational Site
North Adelaide, South Australia, Australia
Pfizer Investigational Site
Clayton, Victoria, Australia
Pfizer Investigational Site
Perth, Western Australia, Australia
Pfizer Investigational Site
Darlinghurst, , Australia
Pfizer Investigational Site
Chicoutimi, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Ste-Foy, Quebec, Canada
Pfizer Investigational Site
Aalborg, , Denmark
Pfizer Investigational Site
Arhus C, , Denmark
Pfizer Investigational Site
Dijon, , France
Pfizer Investigational Site
Nantes, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Kopavogur, , Iceland
Pfizer Investigational Site
Oslo, , Norway
Pfizer Investigational Site
Oslo, , Norway
Pfizer Investigational Site
Parow, Cape Town, South Africa
Pfizer Investigational Site
Bellville, Western Cape, South Africa
Pfizer Investigational Site
Bloemfontein, , South Africa
Pfizer Investigational Site
Cape Town, , South Africa
Pfizer Investigational Site
Gothenburg, , Sweden
Pfizer Investigational Site
Linköping, , Sweden
Pfizer Investigational Site
Malmo, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
, ,
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A5091026
Identifier Type: -
Identifier Source: org_study_id